Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)

What Was Tested

The trial (phase 1) is built around Semaglutide.

The purpose of this research study is to evaluate the feasibility of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight or obesity.

It had two arms (groups): Semaglutide (experimental) and Wait-list control (no intervention).

The registry classes the interventions as drug.

More on the Plan

This study aims to evaluate the feasibility and acceptability of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight/obesity.

This study will also examine changes in alcohol use disorder and weight.

Who Took Part

The registry lists 4 actual participants took part.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Provision of signed and dated informed consent form. Stated willingness to comply with all study procedures and availability for the duration of the study (up to 6 months: 3-month treatment plus 3-month follow up). Age 18 and older. Have a BMI ≥30 (or BMI ≥27 with a medical comorbidity) and BMI ≤50 kg/m2. Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy within the past seven years.

The full record lists 9 inclusion and 19 exclusion criteria; among the exclusions: any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within the past 60 days prior to screening; history or presence of chronic or recurrent pancreatitis; history of malignant neoplasms within the past 5 years prior to screening.

How the Study Was Run

It was run as a randomized, parallel-group and single-blind study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Only one side, usually the participants, was kept unaware of whether Semaglutide was given.

Those kept unaware of assignments: outcomes assessor.

It started in 2026-03-26 with completion listed for 2027-02.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Percent weight change (time frame: Baseline, Week 12, 6-month follow-up). Mean drinks per calendar day to assess alcohol use (time frame: Baseline, Week 4, Week 8, Week 12, 6-month follow-up). Mean drinks per drinking day to assess Alcohol use (time frame: Baseline, Week 4, Week 8, Week 12, 6-month follow-up).

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Semaglutide in 4 people.

Its size is small, so on its own it can only give an early look.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.